Introduction
============

Patients presenting with inoperable lung tumors are generally treated with conventionally fractionated radiotherapy. To improve local control and survival, researchers in the past decade have explored various means of delivering high doses of radiation in shorter intervals \[[@B1]\]. Lung tumors have been treated with relatively tight margins (10 mm) utilizing a body frame and abdominal compression to restrict lung motion \[[@B2]\]. This enhanced precision has facilitated the safe delivery of highly effective hypofractionated doses of radiation quickly to peripheral lung tumors \[[@B3]-[@B16]\]. However, for central lung tumors, treatment related deaths have been attributed to radiation induced bronchial and esophageal injury \[[@B5],[@B13]\]. An ongoing Radiation Therapy Oncology Group (RTOG) protocol is exploring potentially safer 5 fraction treatment regimens for small (\< 5 cm) centrally located non-small cell lung cancers (NSCLCs) \[[@B17]\].

The CyberKnife^®^System (Accuray Incorporated, Sunnyvale, CA) has been successfully employed at Georgetown University Hospital since early 2002 to treat stationary extracranial tumors \[[@B18]\]. With the introduction of the Synchrony™ motion tracking module in 2004, small peripheral and perihilar lung tumors that move with respiration have been successfully treated using tighter margins than previously feasible \[[@B19],[@B20]\]. Here we report clinical results from 20 consecutive patients with hilar lung tumors abutting or invading the mainstem bronchus, treated in 5 fractions using the CyberKnife System with Synchrony™.

Methods and Materials
=====================

Eligibility
-----------

This retrospective review of an established departmental treatment policy was approved by the Georgetown University institutional review board. Consecutively treated patients between October 2005 and October 2009 with pathologically confirmed inoperable primary hilar lung cancers or hilar lung metastases were reviewed. A tumor was considered a \"hilar lung tumor\" if it abutted or invaded the mainstem bronchus. Baseline studies included PET/CT imaging with iodinated IV contrast as clinically feasible.

Fiducial Placement
------------------

Tracking based on translational and rotational target information requires the use of a minimum of 3 non-collinear fiducials to be visible on the orthogonal images of the CyberKnife x-ray targeting system. Three to five gold fiducials measuring 0.8-1 mm in diameter by 3-7 mm in length (Item 351-1 Best Medical International, Inc., Springfield, VA) were placed in or near the tumors via bronchoscopy as previously described \[[@B21]\].

Treatment Planning
------------------

Fine-cut (1.25 mm) treatment planning CT\'s were obtained following fiducial placement during a full inhalation breath hold with the patient in the supine treatment position. Gross tumor volumes (GTV) were contoured utilizing mediastinal windows. A treatment plan was generated using the TPS 5.2.1 non-isocentric, inverse-planning algorithm with tissue density heterogeneity corrections for lung based on an effective depth correction. The radiation dose was divided into 5 equal fractions of 6 to 8 Gy, prescribed to an isodose line that covered at least 95% of the planning treatment volume (PTV = GTV). Guidelines for dose limits to critical central thoracic structures are provided in Table [1](#T1){ref-type="table"}. In general, prescribed doses were increased with clinical experience.

###### 

Radiation maximum point dose limits

  Adjacent Structure   Maximum Point Dose Limit (Gy) (total for 5 fractions)
  -------------------- -------------------------------------------------------
  Spinal cord          25
                       
  Left ventricle       30
                       
  Esophagus            40
                       
  Major bronchus       50

Treatment Delivery
------------------

Patients were treated in the supine position with their arms at their sides. A form-fitting vest containing 3 red light-emitting surface markers was attached to the surface of the patient\'s anterior torso in the region of maximum chest and upper abdominal respiratory excursion. These markers projected to an adjustable camera array in the treatment room. Precise patient positioning was accomplished utilizing the automated patient positioning system. The internal fiducials were located using orthogonal x-ray images acquired with ceiling-mounted diagnostic x-ray sources and corresponding amorphous silicon image detectors secured to the floor on either side of the patient.

Prior to initiating treatment, an adaptive correlation model was created between the fiducial positions as periodically imaged by the x-ray targeting system and the light-emitting markers as continuously imaged by the camera array. During treatment delivery the tumor position was tracked using the live camera array signal and correlation model, and the linear accelerator was moved by the robotic arm in real time to maintain alignment with the tumor. Fiducials were imaged prior to the delivery of every third beam for treatment verification and to update the correlation model.

Follow-up Studies
-----------------

Patients were followed with physical examination and PET/CT imaging at 3 to 6 month intervals. Local tumor recurrence was defined as progression of the treated tumor on PET/CT imaging. Biopsies were obtained when clinically indicated. Early treatment response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee \[[@B22]\]. Toxicities were scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 \[[@B23]\].

Statistical Analysis
--------------------

Statistical analysis was performed with the MedCalc 11.1 statistical package. The follow-up duration was defined as the time from the date of completion of treatment to the last date of follow-up or the date of death. Actuarial local control and overall survival were calculated using the Kaplan-Meier method.

Results
=======

Patient and Tumor Characteristics
---------------------------------

Twenty consecutive patients (10 men and 10 women) were treated over a 4-year period (Table [2](#T2){ref-type="table"}). Three patients presented with primary lung tumors (adenocarcinoma 1, squamous cell carcinoma 2) and 17 with hilar lung metastases (NSCLC 7, renal cell carcinoma 3, sarcoma 2, colon cancer 2, breast cancer 1, mesothelioma 1 and adenoid cystic cancer 1). The patients with primary lung cancer were treated with radiosurgery due to severe pulmonary dysfunction. The mean gross tumor volume (GTV) was 73 cc (range, 23 - 324 cc). Bronchoscopy for fiducial placement documented gross mainstem endobronchial tumor in 3 patients.

###### 

Patient and Tumor Characteristics

  Patient   Age   Sex   Performance Status (ECOG)   Symptom   Category     Histology        GTV (cc)   Mainstem Endobronchial Tumor
  --------- ----- ----- --------------------------- --------- ------------ ---------------- ---------- ------------------------------
  1         62    M     2                           Cough     Metastasis   NSCLC            152        No
                                                                                                       
  2         67    F     0                           SOB       Metastasis   Sarcoma          179        No
                                                                                                       
  3         79    M     2                           SOB       Primary      NSCLC            137        No
                                                                                                       
  4         71    F     2                           Cough     Primary      NSCLC            221        No
                                                                                                       
  5         65    F     2                           SOB       Primary      NSCLC            68         No
                                                                                                       
  6         13    M     0                           None      Metastasis   Sarcoma          44         No
                                                                                                       
  7         76    F     1                           Cough     Metastasis   NSCLC            41         Yes
                                                                                                       
  8         69    M     2                           Pain      Metastasis   NSCLC            68         No
                                                                                                       
  9         61    F     0                           SOB       Metastasis   Renal            182        No
                                                                                                       
  10        59    M     0                           None      Metastasis   NSCLC            38         No
                                                                                                       
  11        65    M     1                           SOB       Metastasis   Mesothelioma     324        Yes
                                                                                                       
  12        23    F     0                           None      Metastasis   Colon            39         No
                                                                                                       
  13        49    M     0                           Cough     Metastasis   Renal            58         No
                                                                                                       
  14        46    M     0                           SOB       Metastasis   Colon            141        No
                                                                                                       
  15        81    F     1                           Cough     Metastasis   NSCLC            50         No
                                                                                                       
  16        71    M     1                           SOB       Metastasis   NSCLC            78         No
                                                                                                       
  17        82    F     0                           None      Metastasis   NSCLC            23         No
                                                                                                       
  18        51    F     0                           SOB       Metastasis   Breast           64         No
                                                                                                       
  19        58    F     0                           Cough     Metastasis   Salivary Gland   87         No
                                                                                                       
  20        62    M     0                           SOB       Metastasis   Renal            111        Yes

Treatment Characteristics
-------------------------

Treatment plans were composed of hundreds of pencil beams delivered using a single 20 to 40-mm diameter collimator (median, 30 mm). Radiation was delivered in 5 equal fractions of 6 to 8 Gy each to a median prescription isodose line of 76% (range, 70-80%). The median dose delivered to the prescription isodose line over an average of 6 days (range, 5-8) was 35 Gy (range, 30-40 Gy). The resulting mean maximum point doses delivered to the esophagus and mainstem bronchus were 25 Gy (range, 11 - 39 Gy) and 42 Gy (range, 30 - 49 Gy), respectively.

Early Clinical and Radiographic Response
----------------------------------------

All patients underwent clinical follow-up, and 14 patients reported symptomatic relief within 1 month of treatment and 2 patients reported relief by 4 months. Of the 17 patients with early radiographic follow-up, 4 patients experienced partial responses and 13 patients had stable disease at 3 - 6 months. There was no local disease progression within the 6-month follow-up interval. Furthermore, 13 patients with serial PET/CT imaging exhibited early declines in the maximum standardized uptake values (Figure [1](#F1){ref-type="fig"}).

![**Right hilar metastasis treatment planning PET/CT with a tumor SUV~max~of 9.6 (A), planned radiation dose distribution (B: the planning treatment volume is shown in red and the 35 Gy isodose line in blue), and PET/CT at 6 months post-treatment (C) shows an excellent response with a tumor SUV~max~of 2.7**.](1756-8722-3-39-1){#F1}

Local Control and Survival
--------------------------

Despite excellent early clinical and radiographic responses, local control and survival outcomes beyond 6 months were poor. At a median follow-up of 10 months, the 1-year Kaplan-Meier local control and overall survival estimates were only 63% and 54%, respectively (Figure [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). Deaths were largely attributed to metastatic disease (Table [3](#T3){ref-type="table"}). However, despite limited follow-up and poor survival, 6 local failures were documented. One such failure resulted in a patient\'s death (Figure [4](#F4){ref-type="fig"}).

![**Kaplan-Meier plot of local control**.](1756-8722-3-39-2){#F2}

![**Kaplan-Meier plot of overall survival**.](1756-8722-3-39-3){#F3}

###### 

Clinical Outcomes

  Patient   Vital Status   Survival (Months)   Local Failure (Months)   Cause of Death
  --------- -------------- ------------------- ------------------------ ----------------
  1         Dead           3                   N/A                      Metastases
                                                                        
  2         Dead           4                   N/A                      Metastases
                                                                        
  3         Dead           5                   N/A                      Metastases
                                                                        
  4         Dead           6                   N/A                      Pulmonary
                                                                        
  5         Dead           12                  8                        Metastases
                                                                        
  6         Dead           19                  12                       Metastases
                                                                        
  7         Dead           25                  14                       Metastases
                                                                        
  8         Dead           9                   8                        Local Failure
                                                                        
  9         Alive          N/A                 N/A                      N/A
                                                                        
  10        Alive          N/A                 N/A                      N/A
                                                                        
  11        Dead           7                   N/A                      Fistula
                                                                        
  12        Alive          N/A                 N/A                      N/A
                                                                        
  13        Dead           16                  N/A                      Metastases
                                                                        
  14        Alive          N/A                 15                       N/A
                                                                        
  15        Alive          N/A                 9                        N/A
                                                                        
  16        Alive          N/A                 N/A                      N/A
                                                                        
  17        Alive          N/A                 N/A                      N/A
                                                                        
  18        Alive          N/A                 N/A                      N/A
                                                                        
  19        Alive          N/A                 N/A                      N/A
                                                                        
  20        Dead           3                   N/A                      Metastases

![**Right hilar tumor treatment planning PET/CT with a tumor SUV~max~of 7.0 (A), planned radiation dose distribution (B: the planning treatment volume is shown in red and the 30 Gy isodose line in blue), and PET/CT at 6, and 12 months post-treatment (C and D) show an initial decrease in SUV~max~to 2.5 followed by local recurrence (SUV~max~= 7.2)**.](1756-8722-3-39-4){#F4}

Complications
-------------

Strict maximum point dose constraints were maintained for normal tissues. Immediately following treatment, mild brief fatigue was reported by the majority of patients. Acute Grade II esophagitis, requiring brief hospitalization for IV hydration, was observed in 1 patient with renal cell carcinoma presenting with a relatively large GTV (182 cm^3^) and a high maximum esophageal point dose approaching the limit of 40 Gy. A second patient with severe COPD and progressing metastatic NSCLC developed dyspnea and an infiltrate on CT corresponding to the high dose treatment volume 8 months following CyberKnife treatment (40 Gy). He required temporary supplemental oxygen and his symptoms resolved with conservative treatment over a 4 day hospital stay. Finally, a patient with advanced mesothelioma developed a mainstem bronchus fistula 7 months following treatment and died (Figure [5](#F5){ref-type="fig"}). He was one of 3 patients with gross mainstem endobronchial disease. Additionally, the GTV was relatively large (324 cm^3^) and the mainstem bronchus received a maximum point dose of 49 Gy.

![**Mainstem gross endobronchial tumor prior to treatment (A) and biopsy proven mainstem bronchus tumor necrosis at 7 months (B)**.](1756-8722-3-39-5){#F5}

Discussion
==========

Continuous tracking of respiratory tumor motion and precise beam alignment throughout treatment permits greater dose conformality to the tumor contour and a sharp dose gradient \[[@B19],[@B24]\]. We observed prompt symptomatic relief in 16 patients, likely due to the high dose per fraction. Furthermore, within 6 months of treatment there was no evidence of local tumor progression and the local control rate at 1 year was 63%. Our results compare favorably to a large RTOG trial of conventionally fractionated radiation therapy for palliation of inoperable NSCLC, which demonstrated palliation of symptoms in 60% and local control in 41% \[[@B25]\]. We conclude that stereotactic radiosurgery with real-time tumor motion tracking and continuous beam correction provides a well-tolerated and effective treatment option for hilar lung tumors.

Prior to proceeding with our institutional study of CyberKnife radiosurgery for hilar lung tumors, maturing data of others suggested that critical central thoracic structures tolerate high-dose hypofractionated radiation poorly \[[@B5]\]. In a phase II trial using 60-66 Gy in 3 fractions for the treatment of NSCLC, severe toxicity was noted in 46% of patients with central lung tumors at 2 years \[[@B5]\]. Therefore, we limited doses to 30-40 Gy in 5 fractions prescribed to the gross tumor volume without additional margin. In the absence of validated esophagus and mainstem bronchus dose limits for stereotactic radiosurgery in 5 fractions, we limited the maximum point doses to 40 Gy and 50 Gy, respectively. Although these dose limits were not exceeded, one patient developed grade II esophagitis and a second patient developed Grade III pneumonitis. Finally, one patient with gross mainstem endobronchial disease developed a fatal airway complication after receiving a maximum point dose of 49 Gy to the mainstem bronchus. In a recently published trial, 6 patients with lung tumors directly involving major airways (i.e. main or lobar bronchi) received 40 to 48 Gy in 4 fractions \[[@B13]\]. As with our study, treatment related toxicity was observed, including 3 patients who developed severe pulmonary toxicity. A single patient with gross mainstem endobronchial disease, who had received 48 Gy in 4 fractions, died of complication related to radiosurgery without evidence of tumor recurrence.

Despite the short survival of treated patients and the aggressive radiation doses used, local control at 1 year was a disappointing 63%. However, in light of dose limiting major bronchus, lung, and esophageal toxicity, further dose escalation beyond 40 Gy is not a feasible approach to improve local control in hilar tumors with a significant endobronchial component. Additional clinical trials that exclude patients with gross mainstem endobronchial disease will be necessary to define the appropriate patient characteristics and doses. Alternatively, this study provides support for investigation of novel radiation sensitizers to enhance the therapeutic ratio of hilar lung tumor radiosurgery.

Conclusion
==========

Hilar lung tumor patients may be treated with frameless stereotactic radiosurgery, resulting in encouraging early clinical responses, acceptable acute toxicity and reliable palliation. However, local control at 1 year remains poor despite aggressive radiation doses and life threatening late toxicity has been reported, especially for tumors with a significant endobronchial component. We propose additional clinical investigation optimizing patient selection and consideration of novel combination treatments with radiation sensitizing drugs.
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